Literature DB >> 9675448

Pharmacodynamics of fluoroquinolones in experimental models of endocarditis.

D R Andes1, W A Craig.   

Abstract

We calculated the magnitude of various serum pharmacodynamic parameters for fluoroquinolones in models of experimental endocarditis (EE) described in the literature. Nineteen publications contained data that allowed calculation of these parameters. Data were available for eight fluoroquinolones against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus, methicillin-resistant Staphylococcus epidermidis, viridans streptococci, Enterobacter aerogenes, and Pseudomonas aeruginosa in rabbit or rat models. Enterococci were excluded because of poor bactericidal activity. A 24-hour area under the concentration curve (AUC)/minimal inhibitory concentration (MIC) ratio > or = 100, a peak level/MIC ratio > 8, and continuous levels above the time were associated with a significantly lower number of cfu per vegetation after 3-6 days of therapy. The 24-hour AUC/MIC exhibited the best linear correlation with cfu per vegetation after 3-6 days of therapy (r2 = 45%). The pharmacodynamic parameters predictive of efficacy for fluoroquinolones in the treatment of experimental endocarditis are similar to those for other infectious models.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9675448     DOI: 10.1086/514624

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  18 in total

1.  Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.

Authors:  E A Coyle; G W Kaatz; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 2.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

3.  Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.

Authors:  E Hershberger; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection.

Authors:  A P MacGowan; C A Rogers; H A Holt; M Wootton; K E Bowker
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

5.  Garenoxacin treatment of experimental endocarditis caused by viridans group streptococci.

Authors:  Paloma Anguita-Alonso; Mark S Rouse; Kerryl E Piper; James M Steckelberg; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

6.  In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.

Authors:  Olivier Grossi; Jocelyne Caillon; Cedric Arvieux; Cedric Jacqueline; Denis Bugnon; Gilles Potel; Antoine Hamel
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

7.  Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.

Authors:  J M Entenza; Y A Que; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 8.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

9.  Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.

Authors:  F Scaglione; J W Mouton; R Mattina; F Fraschini
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

Review 10.  PK/PD models in antibacterial development.

Authors:  Tony Velkov; Phillip J Bergen; Jaime Lora-Tamayo; Cornelia B Landersdorfer; Jian Li
Journal:  Curr Opin Microbiol       Date:  2013-07-18       Impact factor: 7.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.